Group 1: Policy and Economic Development - The introduction of the "Private Economy Promotion Law" in 2025 aims to stimulate the potential of private enterprises in Nanjing, with policies like the "2025 Work Points for High-Quality Development of Private Economy" being established to support their growth [1] - Nanjing's private enterprises have shown significant growth, with over 90% of the 5,351 high-tech enterprise applications coming from private companies [2] Group 2: Technological Innovation - Nanjing's private enterprises have made breakthroughs in key technologies, contributing to industrial upgrades, with the "Ningke Loan" program providing over 270 billion yuan in technology loans [2] - In the field of humanoid robotics, Inks Intelligent Technology has become a leading player, achieving an annual output of over 100,000 joint modules [3] - Future Brain Technology has developed the X-Brain Ocean spatial sound rendering system, enhancing the auditory experience during performances [3] Group 3: Biotechnology and Medical Innovations - The establishment of the regional technology transfer center has facilitated the registration of equity rights for Nanjing Jingji Biotechnology, marking a significant step in patent commercialization [4] - The center provides financial support and technical guidance, allowing companies like Jingji to focus on clinical challenges without financial constraints [5] Group 4: Foreign Trade and Market Expansion - In 2025, Nanjing's private enterprises accounted for 2,219.6 billion yuan in import and export volume, representing 41.3% of the city's total, highlighting their role as a stabilizing force in foreign trade [6] - Companies like Jicui Intelligent Manufacturing have seen significant growth in overseas sales, with orders for cleaning robots reaching 800 units [7] Group 5: Emerging Enterprises and Market Trends - Nanjing has seen the emergence of new private enterprises, with five new listings expected by 2025, and over 70% of specialized and innovative enterprises being private [10] - Companies like Vili Zhibo Biotechnology have gained recognition for their innovative treatments, while Nanjing Xuankai Network Technology is capitalizing on the growing market for AI-driven media [11][12]

Group 1 - The core point of the article is that the first patient has successfully received treatment with the drug Opalizumab (LBL-024) in a Phase Ib/II clinical trial for recurrent or metastatic triple-negative breast cancer (TNBC) [1] - The clinical trial is an open-label, multi-center study led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital, aiming to evaluate the efficacy and safety of Opalizumab alone or in combination with albumin-bound paclitaxel for TNBC patients [1] - The drug Opalizumab is a bispecific antibody targeting both PD-L1 and 4-1BB, and it is the first targeted therapy for the 4-1BB receptor to reach the registration clinical stage for extra-pulmonary neuroendocrine carcinoma [2] Group 2 - In two clinical trials in China, Opalizumab has shown encouraging efficacy signals and good safety profiles, whether used as a monotherapy or in combination with chemotherapy for advanced extra-pulmonary neuroendocrine carcinoma [3] - The company received approval from the National Medical Products Administration (NMPA) in April 2024 to conduct a single-arm registration clinical trial and obtained breakthrough therapy designation (BTD) in October 2024 for treating advanced extra-pulmonary neuroendocrine carcinoma [3] - Cancer is a leading cause of morbidity and mortality globally, with breast cancer being the second most common cancer after lung cancer, and TNBC represents a subtype with high malignancy and poor prognosis, accounting for about 15% to 20% of all breast cancer cases [4]